Advertisement
Canada markets open in 6 hours 40 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7332
    +0.0009 (+0.12%)
     
  • CRUDE OIL

    84.02
    +0.45 (+0.54%)
     
  • Bitcoin CAD

    87,916.26
    +275.81 (+0.31%)
     
  • CMC Crypto 200

    1,391.44
    -5.10 (-0.37%)
     
  • GOLD FUTURES

    2,351.30
    +8.80 (+0.38%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,783.00
    +215.50 (+1.23%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.